NASDAQ:OBLN - Obalon Therapeutics Stock Price, Forecast & News

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

Shares of Obalon Therapeutics reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split.

Obalon Therapeutics Inc (NASDAQ:OBLN) released its earnings results on Friday, November, 8th. The company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($3.50) by $2.89. The company had revenue of $0.33 million for the quarter, compared to the consensus estimate of $2.20 million. Obalon Therapeutics had a negative net margin of 607.48% and a negative return on equity of 228.96%. View Obalon Therapeutics' Earnings History.

Obalon Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Obalon Therapeutics.

Obalon Therapeutics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

4 brokers have issued 12 month price objectives for Obalon Therapeutics' shares. Their forecasts range from $10.00 to $30.00. On average, they expect Obalon Therapeutics' share price to reach $20.63 in the next twelve months. This suggests a possible upside of 1,085.3% from the stock's current price. View Analyst Price Targets for Obalon Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Obalon Therapeutics.

News stories about OBLN stock have trended very negative this week, InfoTrie reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Obalon Therapeutics earned a news impact score of -3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Obalon Therapeutics.

Some companies that are related to Obalon Therapeutics include STRATA Skin Sciences (SSKN), Delcath Systems (DCTH), Arch Therapeutics (ARTH), Invo Bioscience (IVOB), Interpace Diagnostics Group (IDXG), T2 Biosystems (TTOO), Neovasc (NVCN), Biostage (BSTG), RA Medical Systems (RMED), DarioHealth (DRIO), Titan Medical (TMDI), Endologix (ELGX), Lianluo Smart (LLIT), Hancock Jaffe Laboratories (HJLI) and Atossa Genetics (ATOS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), Onconova Therapeutics (ONTX), Opko Health (OPK), Titan Pharmaceuticals (TTNP), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Zynerba Pharmaceuticals (ZYNE).

(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.

Obalon Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Oxford Asset Management LLP (0.55%). Company insiders that own Obalon Therapeutics stock include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Neil Drake, Nooshin Hussainy, Parters Vii L P Domain and William J Plovanic. View Institutional Ownership Trends for Obalon Therapeutics.

OBLN stock was purchased by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP. Company insiders that have bought Obalon Therapeutics stock in the last two years include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Neil Drake, Nooshin Hussainy, Parters Vii L P Domain and William J Plovanic. View Insider Buying and Selling for Obalon Therapeutics.

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OBLN stock can currently be purchased for approximately $1.74.

Obalon Therapeutics has a market capitalization of $13.45 million and generates $9.10 million in revenue each year. The company earns $-37,380,000.00 in net income (profit) each year or ($19.60) on an earnings per share basis. Obalon Therapeutics employs 100 workers across the globe.View Additional Information About Obalon Therapeutics.

The official website for Obalon Therapeutics is http://www.obalon.com/.

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected]